Want to see IN:BAJAJHCARE full AI Analyst Report?
BAJAJHCARE Stock Chart & Stats
₹418.50
-₹31.80(-5.51%)
At close: 4:00 PM EST
₹418.50
-₹31.80(-5.51%)
Day’s Range― - ―
52-Week Range₹272.45 - ₹552.55
Previous CloseN/A
Volume215.90K
Average Volume (3M)4.99K
Market Cap
₹11.56B
Enterprise Value₹12.18B
Total Cash (Recent Filing)₹379.87M
Total Debt (Recent Filing)₹2.49B
Price to Earnings (P/E)68.7
Beta1.25
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)5.06
Shares Outstanding33,662,663
10 Day Avg. Volume2,706
30 Day Avg. Volume4,987
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)1.72
Price to Sales (P/S)1.50
P/FCF Ratio-149.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diverse Manufacturing & Revenue StreamsBajaj Healthcare's integrated manufacturing across APIs, intermediates, finished dosages and contract manufacturing provides durable revenue diversification. Serving both domestic and export markets with large-scale capabilities supports steadier order flow, reduces single-customer risk and underpins long-term industrial competitiveness.
Improving LeverageA move to ~0.47 debt-to-equity from prior elevated levels materially improves solvency and lowers refinancing strain. Stronger leverage supports greater financial flexibility for working capital, capex or R&D, reduces interest burden in future cycles and strengthens resilience to industry downturns.
Revenue Recovery & Margin ImprovementThe FY2026 revenue rebound and higher gross margin suggest recovering demand, improved product mix or better cost control. With operating margins at mid-teens on EBITDA, the company can convert operational leverage into sustained cash generation if below-the-line volatility is managed, supporting durable profitability.
Bears Say
Weak Net ProfitabilityA very low net margin and a prior major loss signal fragile bottom-line durability. Low net profitability reduces retained earnings, weakens returns to shareholders and leaves little buffer against cost or demand shocks, undermining long-term earnings quality despite healthier gross and EBITDA margins.
Negative Free Cash FlowPersistent negative free cash flow and a history of weak cash conversion increase funding and liquidity risk. Even with operating cashflow recovery, negative FCF limits ability to pay down debt, invest organically or return capital, potentially forcing reliance on external financing during adverse cycles.
Volatile Financial PerformanceHistory of uneven revenue and episodic losses reduces predictability for planning and raises the company's effective cost of capital. Such volatility can strain supplier, customer and lender relationships and complicate long-term strategic execution and investment decisions.
Bajaj Healthcare Ltd News
BAJAJHCARE FAQ
What was Bajaj Healthcare Ltd’s price range in the past 12 months?
Bajaj Healthcare Ltd lowest stock price was ₹272.45 and its highest was ₹552.55 in the past 12 months.
What is Bajaj Healthcare Ltd’s market cap?
Bajaj Healthcare Ltd’s market cap is ₹11.56B.
When is Bajaj Healthcare Ltd’s upcoming earnings report date?
Bajaj Healthcare Ltd’s upcoming earnings report date is Aug 04, 2026 which is in 20 days.
How were Bajaj Healthcare Ltd’s earnings last quarter?
Bajaj Healthcare Ltd released its earnings results on May 08, 2026. The company reported -₹7.16 earnings per share for the quarter, missing the consensus estimate of N/A by -₹7.16.
Is Bajaj Healthcare Ltd overvalued?
According to Wall Street analysts Bajaj Healthcare Ltd’s price is currently Overvalued.
Does Bajaj Healthcare Ltd pay dividends?
Bajaj Healthcare Ltd pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.24%. See more information on Bajaj Healthcare Ltd dividends here
What is Bajaj Healthcare Ltd’s EPS estimate?
Bajaj Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bajaj Healthcare Ltd have?
Bajaj Healthcare Ltd has 33,662,663 shares outstanding.
What happened to Bajaj Healthcare Ltd’s price movement after its last earnings report?
Bajaj Healthcare Ltd reported an EPS of -₹7.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.883%.
Which hedge fund is a major shareholder of Bajaj Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:BAJAJHCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bajaj Healthcare Ltd
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 amino 1 adamantanol, N boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Hester Biosciences Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Themis Medicare Limited
―








